GFAP and myeloid sarcoma: Emerging biomarkers, such as glial fibrillary acidic protein (GFAP), chitinase-3-like protein 1 (CHI3L1), and metabolomic indicators, demonstrate promise in refining our understanding of progressive MS phenotypes and tailoring patient-specific care.